Long-term quality of life of testicular cancer patients differs according to applied adjuvant treatment and tumour type

Author:

Heinzelbecker Julia1,Kaßmann Karla1,Ernst Simone1,Meyer-Mabileau Pia1,Germanyuk Aleksandra1,Zangana Miran1,Wagenpfeil Gudrun2,Ohlmann Carsten H.1,Cohausz Maximilian1,Stöckle Michael1,Lehmann Jan1

Affiliation:

1. Department of Urology and Pediatric Urology, Saarland University Medical Centre and Saarland University

2. Institute of Medical Biometry, Epidemiology and Medical Informatics, Saarland University Campus Homburg/Saar

Abstract

Abstract Purpose To evaluate quality of life (QoL) in long-term testicular cancer (TC) survivors. Methods QoL was assessed in TC patients treated between March 1975 and December 2004 using the EORTC-QLQ-C30 questionnaire, including a TC module. Assessment was performed at two time points (2006: n = 201/625 (32.2%), median FU: 12.9 y (1.1–30.9); 2017: 91/201 (45.3%), median FU: 26.2 y (13.0-41.2)). Patients were grouped according to treatment strategy, tumour entity, clinical stage and prognosis group. Linear and multiple linear regression analyses were performed, with age and time of follow-up as possible confounders. Results Radiation therapy (RT), compared to retroperitoneal lymph node dissection (RPLND), was associated with significantly higher impairment of global QoL, as well as physical, role and emotional function; fatigue; nausea; pain; insomnia; appetite loss; constipation; and poor body image. When correcting for age and time of follow-up, only physical function (2017: β= -9.038; t(84)= -2.03; p = 0.045), role function (2017: β= -12.764; t(84)= -2.00; p = 0.048), emotional function (2006: β= -9.501; t(183)= -2.09; p = 0.038) and nausea (2006: β = 6.679; t(185) = 2.70; p = 0.008) remained statistically significant. However, RT was associated with a lower impairment of sexual enjoyment (2017: symptoms: β = 26.831; t(64) = 2.66; p = 0.010; functional: β = 22.983; t(65): 2.36; p = 0.021). Chemotherapy (CT), compared to RPLND, even after correction, was associated with a higher impairment of role (2017: β= -16.944; t(84)= -2.62; p = 0.011) and social function (2017: β= -19.160; t(79)= -2.56; p = 0.012), more insomnia (2017: β = 19.595; t(84) = 2.25; p = 0.027) and greater concerns about infertility (2017: β = 19.830; t(80) = 2.30; p = 0.024). In terms of tumour type, nonseminomatous germ cell tumour (NSGCT) compared to seminoma patients had significantly lower impairment of global QoL and physical and emotional function; less appetite loss, dyspnoea, pain and nausea; better future perspective; body image problems and greater treatment satisfaction. However, after correction, only nausea (2006: β= -4.659; t(187)= -2.17; p = 0.031), appetite loss (2006: β= -7.554; t(188)= -2.77; p = 0.006) and future perspective (2006: β= -12.146; t(175)= -2.08; p = 0.039) remained statistically significant. On the other hand, NSGCT was associated with higher impairment in terms of sexual problems (2006: β = 16.759; t(145) = 3.51; p < 0.001; 2017: β = 21.207; t(63) = 2.73; p = 0.008) and sexual enjoyment (2017: β= -24.224; t(66)= -2.76; p = 0.008). Conclusions The applied adjuvant treatment and the tumour entity had a significant impact on the long-term QoL of TC survivors. Both radio- and chemotherapy had a negative impact compared to patients treated with RPLND, except for on sexual concerns. NSGCT patients had a lower impairment of QoL compared to seminoma patients, except in terms of sexual concerns. Implications for Cancer Survivors: The aims of the study were to raise awareness of aspects of long-term and late effects on quality of life in TC survivors; offer supportive care, such as psycho-oncological support or lifestyle modification, if a deterioration in quality of life is noticed; and avoid toxic treatment opportunities without compromising a cure whenever possible.

Publisher

Research Square Platform LLC

Reference42 articles.

1. Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data;Cornet C;Eur J Cancer,2014

2. Long-term Morbidity of Testicular Cancer Treatment;Fung C;Urol Clin North Am,2015

3. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up;Haugnes HS;J Clin Oncol,2012

4. Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy;Kliesch S;Urol Int,2021

5. Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort;Hellesnes R;J Clin Oncol,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3